- Home
- MSB vs NPCE Comparison
MSB vs NPCE Comparison
Compare MSB & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- NPCE
- Stock Information
- Founded
- MSB 1961
- NPCE 1997
- Country
- MSB United States
- NPCE United States
- Employees
- MSB N/A
- NPCE N/A
- Industry
- MSB Metal Mining
- NPCE Medical Specialities
- Sector
- MSB Basic Materials
- NPCE Health Care
- Exchange
- MSB Nasdaq
- NPCE Nasdaq
- Market Cap
- MSB 320.9M
- NPCE 292.9M
- IPO Year
- MSB N/A
- NPCE 2021
- Fundamental
- Price
- MSB $30.92
- NPCE $9.15
- Analyst Decision
- MSB
- NPCE Strong Buy
- Analyst Count
- MSB 0
- NPCE 6
- Target Price
- MSB N/A
- NPCE $16.67
- AVG Volume (30 Days)
- MSB 48.2K
- NPCE 205.3K
- Earning Date
- MSB 01-01-0001
- NPCE 08-12-2025
- Dividend Yield
- MSB 22.43%
- NPCE N/A
- EPS Growth
- MSB 335.65
- NPCE N/A
- EPS
- MSB 7.12
- NPCE N/A
- Revenue
- MSB $25,894,592.00
- NPCE $88,570,000.00
- Revenue This Year
- MSB N/A
- NPCE $22.13
- Revenue Next Year
- MSB N/A
- NPCE $6.07
- P/E Ratio
- MSB $4.34
- NPCE N/A
- Revenue Growth
- MSB N/A
- NPCE 23.32
- 52 Week Low
- MSB $16.55
- NPCE $5.45
- 52 Week High
- MSB $37.00
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- MSB 54.91
- NPCE 51.74
- Support Level
- MSB $30.68
- NPCE $8.61
- Resistance Level
- MSB $33.25
- NPCE $8.99
- Average True Range (ATR)
- MSB 1.06
- NPCE 0.53
- MACD
- MSB -0.24
- NPCE 0.11
- Stochastic Oscillator
- MSB 27.41
- NPCE 75.00
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.